Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: An open-label study

Psychiatry

Volumn 7, Issue 1, 2010, Pages 17-24

  Rais, Alina R ^a   Williams, Kristi ^b   Rais, Theodor ^a   Singh, Tanvir ^a   Tamburrino, Marijo ^b  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^b UTMC   (United States)

Author keywords

Agitation; Geriatric; Inpatient; Population; Ziprasidone

Indexed keywords

HALOPERIDOL; LORAZEPAM; ZIPRASIDONE;

ACUTE PSYCHOSIS; AGED; AGITATION; ARTICLE; BEHAVIORAL ACTIVITY RATING SCALE; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; DELIRIUM; DELIRIUM RATING SCALE; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR DEPRESSION; MALE; PSYCHOSIS; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 77649096132     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Finkel SI, Lyons JS, Anderson RL. A brief agitation rating-scale (BARS) for nursing-home elderly. J Am Geriatr Soc. 1993;41(1):50-2.
2. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone IM Study Group. J Clin Psychiatry. 2000;61(12):933-941.
3. Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs. 2002;16(4):219-228.
4. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Rockville, MD: 1974.
5. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology. 2001;155(2):128-134.
6. Leso L, Schwartz TL. Ziprasidone treatment of delirium. Psychosomatics. 2002;43(1):61-62.
7. Miceli J, Wilner K, Folger C, et al. Pharmacokinetics of intramuscular ziprasidone in schizophrenic patients: Population pharmacokinetic modeling. Eur Neuropsychopharmacol. 1998;8(S2):215.
8. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract. 2002;8(2):81-97.
9. Brook S, Swift R, Harrigan EP, Tensfeldt T. The tolerability and efficacy of intramuscular ziprasidone. Psychopharmacol Bull. 1997;33(3):498.
10. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dosefinding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18(4):296-304.
11. Physicians' Desk Reference: Companion Guide 56th Edition. Montvale, NJ: Medical Economics Company, Inc.;2002.
12. Swift RH, Harrigan EP, van Kammen DP. A comparison of intramuscular ziprasidone with IM haloperidol. Schizophr Res. 1999;36(1-3):298.
13. Zimbroff DL, Allen MH, Battaglia J, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectrums. 2005;10(9):1-15.
14. Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo controlled trial. Psychopharmacology. 1998;140(2):173-184.
15. Swift RH, Harrigan EP, Cappelleri JC, et al. Validation of the behavioural activity rating scale (BARS)(TM): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36(2):87-95.
16. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer Antipsychotics on extrapyramidal function. CNS Drugs. 2002;16(1):23-46.
17. Barak Y, Doron M, Igor P, et al. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia. Am J Geriatr Psychiatry. 2006;14(7):629-633.
18. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in Parkinsonian patients with psychosis. Clin Neuropharmacol. 2005;28(3):111-114.
19. Berkowitz A. Ziprasidone for dementia in elderly patients: A case series. Int Psychogeriatr. 2003;15:223-224.
20. Greco KE, Tune LE, Brown FW, Van Horn WA. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. J Clin Psychiatry. 2005;66(7):928-929.
21. Cole SA, Saleem R, Shea WP, et al. Ziprasidone for agitation or psychosis in dementia: four cases. Int J Psychiatry Med. 2005;35(1):91-98.
22. Kohen I, Preval H, Southard R, Francis A. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. Am J Geriatr Pharmacother. 2005;3(4):240-245.
23. Rappaport SA, Marcus RN, Manos G, et al. A randomized, double blind, placebo controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with alzheimer's, vascular, or mixed dementia. J Am Med Dir Assoc. 2009;10(1):21-27.
24. Food and Drug Administration. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. (Accessed November 3, 2005, at http://www.fda.gov/cder/drug/advisory/antipsychotics.htm
25. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
26. Trzepacz PT, Baker RW, Greenhouse J. A symptom rating-scale for delirium. Psychiatry Res. 1988;23(1):89-97.
27. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for ziprasidone mesylate for intramuscular injection. February 15, 2001. Available at: http://www.fda.gov/ohrms/dockets/AC/01/briefing/3685b2-02-pfizer-appendix. pdf. Accessed September 17, 2009.
28. Barnes TRE. A rating-scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
29. Reeves KR, Swift RH, Harrigan EP. Intramuscular ziprasidone (10mg and 20mg) in patients with psychosis and acute agitation. Schizophr Res. 1999;36(1-3):293.
30. Rocha FL, Hara C, Ramos MG, et al. An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. Dement Geriatr Cogn Disord. 2006;22(5-6):445-448.
31. Case DE. Barriers to progress: the impact of tolerability problems. Int Clin Psychopharmacol. 2001;16(1):S15-S19.
32. Tandon, R. Safety and tolerability: How do newer generation "atypical" antipsychotics compare? Psychiatr Q. 2002;73(4):297-311.
33. Shiah I-S, Lin C-L, Mao, W-C, Luu, S-U. Ziprasidone in the treatment of Parkinson's disease psychosis. Eur Psychiatry. 2006;21:578-579.
34. Oechsner M, Korchounov A. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease. Hum Psychopharmacol. 2005;20:203-205.